2010-08-26
The Agency for
Healthcare Research and Quality (AHRQ) has released a technology assessment
titled “Consideration of Evidence on
Antiemetic Drugs for Nausea and Vomiting Associated with Chemotherapy or
Radiation Therapy in Adults.”
This AHRQ technology assessment can assist physicians by providing a review of
current literature on the following questions:
- What
are the comparative overall benefits of antiemetic regimens that consist
of a 5-HT3 antagonist plus a corticosteroid, with or without aprepitant,
given to prevent and/or treat nausea and/or vomiting caused by emetogenic
anticancer chemotherapy and/or radiation? Outcomes of interest include (at
least): ability to control nausea and vomiting; ability to tolerate
sequential chemotherapy sessions; quality of life measures.
- What
are the harms of antiemetic regimens that consist of a 5-HT3 antagonist
plus a corticosteroid, with or without aprepitant, given to prevent and/or
treat nausea and/or vomiting caused by emetogenic anticancer chemotherapy
and/or radiation?
Are
there subgroups of patients based on demographics (age, race, gender),
socioeconomic status, other medications, or comorbidities, for which one of
these antiemetic regimens is more effective or associated with fewer adverse
events in the context of emetogenic anticancer chemotherapy and/or radiation?
back to top
